{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-005717","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.580563+00:00","generated_at":"2026-05-16T03:56:23.102706+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Phase 3 Ameluz® PDT meets primary endpoint for AK on extremities/neck/trunk","bullets":["Complete clearance 45.6% (Ameluz®) vs 16.7% (vehicle), p<0.0003 in FAS.","Per protocol set complete clearance 53.2% vs 22.2% (p<0.001).","Study enrolled 172 patients randomized 4:1; lesion clearance rate 73.1% (FAS).","Cosmetic outcomes: 75.2% rated 'good/very good'; 86.3% would choose PDT again.","sNDA submission to FDA planned for Q3 2026 based on these positive results."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-005717","json":"https://secwatch.observer/filing/0001493152-26-005717.json","markdown":"https://secwatch.observer/filing/0001493152-26-005717.md","text":"https://secwatch.observer/filing/0001493152-26-005717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/0001493152-26-005717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:56:23.102706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}